Have you wondered why it is called: a gut feeling or a gut instinct?

Transcription

1 Have you wondered why it is called: a gut feeling or a gut instinct? 2500 years ago, Hippocrates said: death sits in the bowels

2 microgut: engage your microbiome! SCIENTIFIC ADVISORY BOARD Luxembourg Centre for Systems Biomedicine University of Luxembourg Center for Applied Nanobiosciences & Medicine University of Arizona Siva Bactavatchalou Dr. Pranjul Shah Paul Wilmes Frederic Zenhausern Co-inventor of HuMiX Co-inventor of HuMiX Technology developed University of Luxembourg by University of Arizona Group leader: Ecosystems Biology Director: Applied centre for Group nanobioscience and medicine in collaboration with funded by

3 Problem Diseases Ulcers Nutrition Obesity Diarrhea Diabetes Cancer IBD Auto Immune Cardio Current models in vitro in vivo animals Expensive, time-consuming & inadequate One compound testing = $6 million animals Success rate < 20% Gastrointestinal tract Lack of representative gastrointestinal model a major hurdle to progress in drug discovery and therapy

4 Value proposition microgut: Emulating Human GI tract on a Chip 4x patents: US Provisional 62/ Shah, P. et al., Nat. Commun. 7:11535 Small intestine A Transverse colon Ascending colon Descending colon B C D microgut B A C D

5 Value proposition microgut: Emulating Human GI tract on a Chip 4x patents: US Provisional 62/ Shah, P. et al., Nat. Commun. 7:11535 HEALTHY GUT MODEL Diet/ Product candidate Toxicity/ Nutri prediction PRODUCT SCREENING Small intestine Transverse colon Ascending colon Descending colon A B C D microgut Metabolites Bacteria B A C D DISEASE MODEL Target Mechanism of action PRODUCT DISCOVERY

6 Our USP 4x patents: US Provisional 62/ Shah, P. et al., Nat. Commun. 7:11535 THE FIRST AUTOMATED, MINIATURIZED AND COMPREHENSIVE MODEL OF THE HUMAN GASTROINTESTINAL TRACT

7 Competition Current STATE OF THE ART SHIME COST > 250K EUR SETUP DEMANDING EXPERIMENTS 60% cultivability of inoculated bacterial communities LAB. SETTING Difficulty to met the exponential growth in demand and scales operations

8 Competition Current STATE OF THE ART SHIME COST > 250K EUR SETUP DEMANDING EXPERIMENTS 60% cultivability of inoculated bacterial communities LAB. SETTING Difficulty to met the exponential growth in demand and scales operations microgut < 20K EUR TRIVIAL 92% cultivability of inoculated bacterial communities With microgut, we wish to democratize gut microbiota research & development and in the process establish microgut as a new standard

9 Business model offers the patent pending microgut as a product to screen compounds (drugs, probiotics) targeted for the human microbiome. Consumable Platform: EUR/pc Consumable: 100 EUR/pc

10 Market HUMAN MICROBIOME MARKET $294m (2019) - $658m (2023) CAGR = 22,3% ( ) CUSTOMER SURVEY Technology ratings Preferred payment option > 20 organizations want to acquire microgut

11 Timeline and growth strategy 1. Product development (1 year) COMMERCIAL VALIDATION 2. Operations and launch of microgut with early adopters (6 months) COMMERCIALIZATION 3. Scaling and worldwide expansion (1 year) Product planning and design Ongoing until August 2016 Productization September March 2017 Testing and optimization March 2017 August 2017 Expansion to North America Investment 1 MILLION EUR 1 MILLION EUR

12 EUR MILLIONS Cumulative sales forecast 9,0 8,0 7,0 6,0 Product development Launch with early adopters Scaling and worldwide expansion 7,65 5,0 4,0 3,0 microgut platform 2,0 1,0 Consumables 1,02 0,0 Y1-H1Y1-H2Y2-H1Y2-H2Y3-H1Y3-H2Y4-H1Y4-H2Y5-H1Y5-H2

13 Team Dr. Pranjul Shah Chief Executive Officer Business Development Co-inventor of microgut Core Team Siva Bactavatchalou VP Operations Marketing & Sales Advisory board Network Luxembourg Centre for Systems Biomedicine First strategic investor Life Sciences Business planning Marketing & Sales MedTech Human microbiome Technology transfer Entrepreneurship Network of experts

14 Thank you for your attention We are interested to know more on the minigut One of the top 3 global pharma giant We have been exploring our options in this space and would be interested in a demo. University in the U.S.A. Please contact me to discuss further on this matter CEO of a biotech company in the U.S.A. The microgut technology is not just a choice, it is the only choice